| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10918270 | Radiotherapy and Oncology | 2015 | 5 Pages |
Abstract
Since all teams identify most dominant lesions, dose escalation to the dominant lesion is feasible. Sufficient dose to the whole prostate may need to be maintained to prevent under treatment of smaller lesions and undetected parts of larger lesions.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Peter Steenbergen, Karin Haustermans, Evelyne Lerut, Raymond Oyen, Liesbeth De Wever, Laura Van den Bergh, Linda G.W. Kerkmeijer, Frank A. Pameijer, Wouter B. Veldhuis, Jochem R.N. van der Voort van Zyp, Floris J. Pos, Stijn W. Heijmink,